Quote | NeuroSense Therapeutics Ltd. (NASDAQ:NRSN)
Last: | $1.08 |
---|---|
Change Percent: | 5.36% |
Open: | $1.06 |
Close: | $1.08 |
High: | $1.13 |
Low: | $0.98 |
Volume: | 1,410,657 |
Last Trade Date Time: | 07/01/2024 03:00:00 am |
News | NeuroSense Therapeutics Ltd. (NASDAQ:NRSN)
NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug PR Newswire Disease progression was slowed by 36% (p=...
2024-06-24 16:02:26 ET More on NeuroSense Therapeutics NeuroSense Therapeutics sheds 6% on $4.5M direct private offering Seeking Alpha’s Quant Rating on NeuroSense Therapeutics Historical earnings data for NeuroSense Therapeutics Financial information ...
Message Board Posts | NeuroSense Therapeutics Ltd. (NASDAQ:NRSN)
Subject | By | Source | When |
---|---|---|---|
If the relationship goes well they might do | McMagyar | investorshub | 06/22/2023 12:14:56 PM |
Just saw its an engagement with bioscam.. Who would | McMagyar | investorshub | 06/22/2023 12:12:56 PM |
$NRSN MomentumIts trading last trade up | THEMASTERS_SON | investorshub | 06/15/2023 7:04:58 PM |
oh yeah news for the day | THEMASTERS_SON | investorshub | 06/15/2023 11:36:18 AM |
$NRSN The gaining | frankyahoo | investorshub | 06/15/2023 6:18:46 AM |
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
5.36%Change Percent:
NeuroSense Therapeutics Ltd. Company Name:
NRSN Stock Symbol:
NASDAQ Market:
NeuroSense Therapeutics Ltd. Website:
NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug PR Newswire Disease progression was slowed by 36% (p=...
NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results PR Newswire Following positive 6-month clinical outcomes from phase 2b (PARADIGM) clinical trial, Company expects additional biomarker and 12-month clinical in the near term ...
NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal PR Newswire CAMBRIDGE, Mass. , June 21, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative ...